DE
30
-2
ZION
52
4
PX
19
3
ALLE
41
-5
UPS
46
-2
PGR
74
4
CCL
33
-6
F
54
2
HP
30
-3
MKC
41
-7
DFS
56
-6
AFL
62
5
DOV
76
-2
MET
43
6
MRK
66
-2
SWK
77
4
IFF
44
-3
LOW
53
-2
UAL
64
10
AEE
45
4
DE
30
-2
ZION
52
4
PX
19
3
ALLE
41
-5
UPS
46
-2
PGR
74
4
CCL
33
-6
F
54
2
HP
30
-3
MKC
41
-7
DFS
56
-6
AFL
62
5
DOV
76
-2
MET
43
6
MRK
66
-2
SWK
77
4
IFF
44
-3
LOW
53
-2
UAL
64
10
AEE
45
4
Financhill
Back

Celldex Therapeutics 10K Form

Buy
58

CLDX
Celldex Therapeutics

Last Price:
40.12
Seasonality Move:
8.17%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CLDX News And Ratings

See the #1 stock for the next 7 days that we like better than CLDX

CLDX Financial Statistics

Sales & Book Value

Annual Sales: $6.88M
Cash Flow: $-33.2M
Price / Cash Flow: 0
Annual Sales: $7.68
Price / Book: 5.12

Profitability

EPS (TTM): -2.92000
Net Income (TTM): $-141.43M
Gross Margin: $0
Return on Equity: -44.69%
Return on Assets: -41.06%

Celldex Therapeutics Earnings Forecast

Key Celldex Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 30 years for CLDX is 0.00%.
  • The Selling, General & Administrative Expenses for CLDX have been equal to 449.14% of Gross Profit Margin.
  • The Research & Development expenses have been 1,714.53% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of CLDX is -2,054.76% of Total Revenues.
  • Per Share Earnings over the last 38 years have been positive in 22 years.

Celldex Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CLDX
CUSIP: 15117B
Website: celldex.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 13.87
Quick Ratio: 13.69

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CLDX Technical Analysis vs Fundamental Analysis

Buy
58
Celldex Therapeutics (CLDX) is a Buy

Is Celldex Therapeutics a Buy or a Sell?